Machine Learning Identification of a Novel Vasculogenic Mimicry-related Signature and FOXM1's Role in Promoting Vasculogenic Mimicry in Clear Cell Renal Cell Carcinoma

Overview

Journal Transl Oncol

Date 2025 Feb 4

PMID 39904282

Authors

Chao Xu

Sujing Zhang

Jingwei Lv

Yilong Cao

Yao Chen

Hao Sun

Shengtao Dai

Bowei Zhang

Meng Zhu

Yuepeng Liu

Junfei Gu

Affiliations

Soon will be listed here.

Abstract

Background: Clear Cell Renal Cell Carcinoma (ccRCC), the predominant subtype of renal cell carcinoma (RCC), ranks among the most common malignancies worldwide. Vasculogenic mimicry (VM) plays a pivotal role in tumor progression, being closely linked with heightened chemoresistance and adverse prognosis in cancer patients. Nonetheless, the broader impact of vasculogenic mimicry-related genes (VRGs) on ccRCC patient prognosis, tumor microenvironment characteristics, and treatment response remains incompletely understood.

Methods: Consensus clustering identified VRG-associated subtypes. We developed a machine learning framework integrating 12 algorithms to establish a consistent VM-related signature (VRG_score). The predictive value of VRG_score for ccRCC prognosis and treatment response was assessed. FOXM1's clinical relevance was explored using the UCLCAN database. FOXM1 expression in tumor and adjacent tissues was assessed using Western Blotting, IHC, RNA-seq, and Chip-qPCR methods, and its regulatory mechanism was confirmed.

Results: We examined VRG mutation and expression patterns in ccRCC at the gene level, identifying two distinct molecular clusters. A consensus VRG_score was formulated using a machine learning computational framework and Cox regression, displaying strong predictive power for prognosis and clinical translation. Additionally, FOXM1 was found to be upregulated in ccRCC, correlating with clinical pathological features and positively regulating PYCR1, thereby activating the PI3K/AKT/mTOR signaling pathway and promoting VM formation.

Conclusion: This study constructed a VM-related signature and revealed that FOXM1 promotes VM formation in renal cell carcinoma through the PYCR1-PI3K/AKT/mTOR signaling axis, serving as a prognostic indicator and potential therapeutic target.

References

Nandi I, Smith H, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V . Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. J Clin Invest. 2023; 133(7). PMC: 10065076. DOI: 10.1172/JCI162324. View

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

Liu X, He H, Zhang F, Hu X, Bi F, Li K . m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022; 13(5):483. PMC: 9122982. DOI: 10.1038/s41419-022-04950-2. View

Wei W, Wang N, Deng M, Dong P, Liu J, Xiang Z . LRPPRC regulates redox homeostasis via the circANKHD1/FOXM1 axis to enhance bladder urothelial carcinoma tumorigenesis. Redox Biol. 2021; 48:102201. PMC: 8645923. DOI: 10.1016/j.redox.2021.102201. View

Li Z, Jiang Y, Liu J, Fu H, Yang Q, Song W . Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway. Int J Oncol. 2023; 63(1). PMC: 10552724. DOI: 10.3892/ijo.2023.5532. View

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

He M, Yang H, Shi H, Hu Y, Chang C, Liu S . Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling. Cancer Lett. 2021; 524:15-28. DOI: 10.1016/j.canlet.2021.08.028. View

van der Schaft D, Seftor R, Seftor E, Hess A, Gruman L, Kirschmann D . Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 2004; 96(19):1473-7. DOI: 10.1093/jnci/djh267. View

Khan M, Khan P, Ahmad A, Fatima M, Nasser M . FOXM1: A small fox that makes more tracks for cancer progression and metastasis. Semin Cancer Biol. 2023; 92:1-15. PMC: 10199453. DOI: 10.1016/j.semcancer.2023.03.007. View

10.

Chang K, Chen Y, Zhang X, Zhang W, Xu N, Zeng B . DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma. Cancer Res. 2023; 83(23):3940-3955. DOI: 10.1158/0008-5472.CAN-22-4001. View

11.

Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018; 24(6):749-757. PMC: 6721896. DOI: 10.1038/s41591-018-0053-3. View

12.

Tan L, Cockshell M, Moore E, Myo Min K, Ortiz M, Johan M . Vasculogenic mimicry structures in melanoma support the recruitment of monocytes. Oncoimmunology. 2022; 11(1):2043673. PMC: 8920250. DOI: 10.1080/2162402X.2022.2043673. View

13.

Castro-Mondragon J, Riudavets-Puig R, Rauluseviciute I, Lemma R, Turchi L, Blanc-Mathieu R . JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2021; 50(D1):D165-D173. PMC: 8728201. DOI: 10.1093/nar/gkab1113. View

14.

Jin J, Xie Y, Zhang J, Wang J, Dai S, He W . Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023; 67:100929. DOI: 10.1016/j.drup.2023.100929. View

15.

Yang W, Li Z, Wang W, Wu J, Li J, Huang X . Vasculogenic mimicry score identifies the prognosis and immune landscape of lung adenocarcinoma. Front Genet. 2023; 14:1206141. PMC: 10282128. DOI: 10.3389/fgene.2023.1206141. View

16.

Liu T, Ortiz J, Taing L, Meyer C, Lee B, Zhang Y . Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011; 12(8):R83. PMC: 3245621. DOI: 10.1186/gb-2011-12-8-r83. View

17.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

18.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

19.

Luo Y, Yang Z, Yu Y, Zhang P . HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. Int J Biol Macromol. 2022; 222(Pt B):2225-2243. DOI: 10.1016/j.ijbiomac.2022.10.014. View

20.

Xiao H, Huang J, Wu H, Li Y, Wang Y . Pro-tumorigenic activity of PYCR1 in gastric cancer through regulating the PI3K/AKT signaling. Heliyon. 2024; 10(5):e26883. PMC: 10918153. DOI: 10.1016/j.heliyon.2024.e26883. View